Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
World J Gastroenterol
; 21(4): 1275-83, 2015 Jan 28.
Article
em En
| MEDLINE
| ID: mdl-25632202
ABSTRACT
AIM:
To investigate the prognostic role of KRAS and BRAF mutations after adjustment for microsatellite instability (MSI) status in Japanese colorectal cancer (CRC) population.METHODS:
We assessed KRAS and BRAF mutations and MSI status in 813 Japanese patients with curatively resected, stageâ I-III CRC and examined associations of these mutations with disease-free survival (DFS) and overall survival (OS) using uni- and multivariate Cox proportional hazards models.RESULTS:
KRAS and BRAF mutations were detected in 312 (38%) of 812 and 40 (5%) of 811 tumors, respectively. KRAS mutations occurred more frequently in females than in males (P=0.02), while the presence of BRAF mutations was significantly associated with the female gender (P=0.006), proximal tumor location (P<0.001), mucinous or poorly differentiated histology (P<0.001), and MSI-high tumors (P<0.001). After adjusting for relevant variables, including MSI status, KRAS mutations were associated with poorer DFS (HR=1.35; 95%CI 1.03-1.75) and OS (HR=1.46; 95%CI 1.09-1.97). BRAF mutations were poor prognostic factors for DFS (HR=2.20; 95%CI 1.19-4.06) and OS (HR=2.30; 95%CI 1.15-4.71). Neither the BRAF by MSI interaction test nor the KRAS by MSI interaction test yielded statistically significant results for DFS and OS.CONCLUSION:
KRAS and BRAF mutations are associated with inferior survival, independent of MSI status, in Japanese patients with curatively resected CRC.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Colorretais
/
Biomarcadores Tumorais
/
Proteínas Proto-Oncogênicas
/
Colectomia
/
Proteínas ras
/
Proteínas Proto-Oncogênicas B-raf
/
Mutação
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article